| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
As of September 30, 2025, the Company had $58.7 million in cash, cash equivalents and short-term investments.In November 2025, ...
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, ...
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15...